Stock Quote
Covance Inc (CVD) (NYSE Arca)
$53.59
23 Nov 2009
+1.32%
$53.59
--
274,761
$54.27
$53.29
$58.95
$32.31
1.05
523,409
CVD
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Herring, Joseph | Chairman of the Board, Chief Executive Officer | 5,410,530 |
| Klitgaard, William | Chief Financial Officer, Corporate Senior Vice President, Treasurer | 1,446,520 |
| Barr, Wendel | Chief Operating Officer, Executive Vice President | 1,765,780 |
Profile
Covance Inc. is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. The Company also provides laboratory testing services to the chemical,... Full Description
Company Address
Covance Inc
210 Carnegie Center
Princeton NJ 08540
P: +1609.4524440
F: +1609.4524769
210 Carnegie Center
Princeton NJ 08540
P: +1609.4524440
F: +1609.4524769
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Charles River Laboratories | $32.59 | +0.15 |
| MDS Inc. | $8.05 | -0.12 |
| PAREXEL International Corporation | $12.88 | +0.33 |
| CVD | Industry | |
|---|---|---|
| P/E(TTM) | 19.07 | 12.80 |
| P/S(TTM) | 1.79 | 29.90 |
| ROI(TTM) | 13.10 | 2.35 |
| ROE(TTM) | 14.11 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.70 |
| EPS Est. (Current Year) | 2.62 |
| Total Revenue | $493.72M |
| Net Income | $50.90M |
| EPS | $0.79 |
